The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.
Manisha Shah
Honoraria - Novartis
Research Funding - ImClone Systems; Novartis
Catherine Lombard-Bohas
No relevant relationships to disclose
Tetsuhide Ito
No relevant relationships to disclose
Edward Wolin
Consultant or Advisory Role - Novartis
Eric Van Cutsem
Research Funding - Novartis
Carolin Sachs
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Robert Winkler
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeremie Lincy
Employment or Leadership Position - Novartis
Timothy Hobday
Consultant or Advisory Role - Novartis
Research Funding - Novartis
James Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech; Novartis